<DOC>
	<DOCNO>NCT01619150</DOCNO>
	<brief_summary>The purpose study investigate pain mechanism affect etoricoxib compare placebo ( inactive medication ) subject painful knee osteoarthritis af 4 week treatment .</brief_summary>
	<brief_title>A Single Center 2-way Crossover Study Investigate Mechanism Action Etoricoxib Subjects With Osteoarthritis Knee Pain</brief_title>
	<detailed_description>Study Rationale : The purpose study investigate pain mechanisms subject painful knee osteoarthritis affect peripheral central action etoricoxib compare placebo 4 week treatment therapy period . The present study utilize set quantitative mechanism base pain biomarkers assess peripheral central pain manifestation OA influence etoricoxib individual manifestation attempt understand explain clinical pain alleviation . Study Treatment : Subjects randomize one 2 sequence treatment : Sequence 1 ( 60 mg/day etoricoxib follow placebo ) Sequence 2 ( placebo follow 60 mg/day etoricoxib ) . The two treatment period 4 week separate washout period least 6 day . Primary Objective : To assess pain mechanism modulate 60 mg daily administration etoricoxib compare placebo subject osteoarthritic ( OA ) knee pain two treatment period 4-weeks . Secondary Objectives : To evaluate change mechanism base experimental pain assessment parameter explain change clinical outcome parameter . To profile drug responders- versus non-responders base pain mechanism involve . To investigate change inflammatory , bone cartilage relate bio-chemical biomarkers explain change either experimental clinical pain parameter .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>1 . Written informed consent ( IRB/IEC specific ) obtain prior initiation protocol require procedure . 2 . Male female 40 75 year age . Females childbearing potential must negative urine pregnancy test screening . 3 . Body weight &gt; 40 kg &lt; 150 kg body mass index ( BMI ) 1940 kg/m2 inclusive . 4 . Idiopathic osteoarthritic knee pain diagnose accordance American College Rheumatology modify clinical classification criterion ( Altman et al , 1986 ) verify radiologically KellgrenLawrence grade I , II III ( Kellgren Lawrence , 1957 ) index knee . The clinical diagnosis OA confirm ACR clinical radiographic criterion classification idiopathic OA base upon follow criterion ( index knee ) : 1 . Knee pain least 14 day per month 3 month study entry . 2 . Osteophytes ( radiographic evidence ) . 3 . And least 1 follow 3 condition : Age &gt; 50 , morning stiffness &lt; 30 minute , crepitus . 4 . Xray image knee joint available confirm OA . Xray image older than12 month use . New photo need confirm diagnostic criterion OA . 5 . For index knee , average bad daily pain score last 14 day prior day 0 must 4.0 9.0 . The 14day average score derive bad daily pain score record diary index knee . 6 . Discontinued use analgesic medication ( include overthecounter analgesics/ NonSteroidal AntiInflammatory Drug least 3 day prior visit 2 ( subject allow limited use analgesic medication ) . 7 . Have agree maintain activity level throughout course study . 1 . Have history recurrent seizure febrile seizure . 2 . Have history frequent and/or severe allergic reaction multiple medication . 3 . Have current recent history , determine investigator delegate , severe , progressive , and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , psychiatric cerebral disease could interfere subject 's participation study . 4 . At screening , abnormality 12lead ECG , opinion investigator , increase risk associate participation study . In addition , subject follow finding exclude : 1 . Confirmed Bazett 's correct QT ( QTcB ) interval &gt; 450 msec men &gt; 470 msec woman screen . If QTcB prolong second ECG take confirm find ; ( additional ECGs may perform require ) , 2 . Bundle branch block conduction abnormality mild first degree atrioventricular block , leave anterior hemi block due leave axis deviation right bundle branch block benign origin i.e . cause cardiac disease , 3 . Irregular rhythm sinus arrhythmia occasional supraventricular ventricular ectopic beat , 4 . History unexplained syncope , 5 . Family history unexplained sudden death sudden death due long QT syndrome , 6 . Twave configuration sufficient quality assess QT interval determination , assess investigator . 5 . Have alanine aminotransaminase &gt; 2.5 time Upper Limit Normal ( ULN ) screening , base reference range local laboratory . Moderate great hepatic impairment . 6 . Have prior renal transplant , current renal dialysis severe renal insufficiency ( determine derive glomerular filtration rate use Cockcroft Gault formula ≤30 ml/min/1,73m² calculate local lab ) , serum creatinine laboratory value &gt; 1.5 time ULN , base reference range local laboratory . 7 . Have active peptic ulcer gastrointestinal bleeding . 8 . Have know inflammatory intestinal disease . 9 . Subject ischemic heart disease , peripheral arterial disease and/or cerebrovascular disease . 10 . Subject congestive heart failure ( NYHA IIIV ) . 11 . Subject uncontrolled arterial hypertension ( &gt; 160/90 ) . 12 . Subject diabetes mellitus document atherosclerosis . 13 . History bronchospasm , acute rhinitis , nasal polyp , angioneurotic edema , urticaria type allergic reaction use acetylic acid NSAID , inclusive COX2 inhibitor . 14 . Is allergic active ingredient etoricoxib one excipients . 15 . Pregnant female , breast feeding planning pregnancy study period . Females childbearing potential , use reliable mean contraception . 16 . Subject active malignancy type history malignancy within last 5 year ( except basal cell carcinoma skin excise prior study start ) . 17 . Are take excluded medication ( analgesic medication ) discontinue screening period ( 3 day prior visit 2 ) . 18 . Subject treatment anticoagulant ( exception acetylsalicylic acid ) , methotrexate rifampicin antihypertensive ( exception Ca+antagonists ) . 19 . Have receive treatment within last 30 day drug receive regulatory approval indication Visit 1 . 20 . Have history substance abuse dependence within past year , exclude nicotine caffeine . 21 . Subject high risk infection ( e.g . leg ulcer , indwell urinary catheter persistent recurrent chest infection subject permanently bed ridden wheelchair bound ) . 22 . Subject history , suspect , demyelinate disease central nervous system ( e.g . multiple sclerosis optic neuritis ) . 23 . Have autoimmune disorder ( include psoriasis ) . 24 . Subject fully understand EPM procedure accord investigator experience . 25 . Investigator site personnel directly affiliate study and/or immediate family participate . Immediate family define spouse , parent , child , sibling , whether biological legally adopt . 26 . Subject diagnosed condition suggestive secondary cause knee OA include limited knee trauma , septic arthritis , inflammatory joint disease , articular fracture , major dysplasia congenital abnormality , ochronosis , acromegaly , hemochromatosis , Wilson 's disease , primary osteochondromatosis . 27 . History surgery ( include arthroscopy ) index knee within 3 month prior visit 1 already plan surgery index knee time . 28 . History significant prior injury index knee within 12 month prior visit 1 . 29 . Subject diagnosed Kellgren Lawrence grade IV index knee . 30 . Use low extremity assistive device knee brace 'shoe lift ' . Use cane hand opposite index knee acceptable . 31 . History prior synovial fluid analysis show White Blood Cell count ≥ 2000 mm3 indicative diagnosis OA index knee . 32 . Have confound painful condition may interfere assessment index knee joint . ( Knee pain predominant pain . Mild OA hand allow , instance ) . 33 . History musculoskeletal arthritic condition may affect interpretation clinical efficacy and/or safety data otherwise contraindicate participation clinical study ( i.e. , currently symptomatic fracture concurrent rheumatic disease limit fibromyalgia , rheumatoid arthritis , gout , pseudogout Paget 's disease Reiter 's syndrome exclude ) . 34 . Have use corticosteroid prior baseline : 1 . Intraarticular injection steroid index knee site index knee within previous 3 month , 2 . Intramuscular corticosteroid injection within previous 3 month , 3 . Oral corticosteroid within previous 1 month . 35 . Have initiate change establish physiotherapy program within last 14 day prior visit 3 . 36 . Have record minimum 10 day diary data last 14 day immediately precede visit 3 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>knee</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>central sensitization</keyword>
	<keyword>mechanical detection</keyword>
	<keyword>pain threshold</keyword>
	<keyword>quantitative sensory test</keyword>
	<keyword>pain biomarkers</keyword>
	<keyword>COX-2 inhibitor</keyword>
	<keyword>etoricoxib .</keyword>
</DOC>